《新股表现》药明巨诺(02126.HK)暗盘高开0.8%报24元
根据辉立交易平台显示,明天挂牌的药明巨诺(02126.HK)暗盘高开0.8%报24元,高低见24.2元/23.8元,现造24.1元,较上市价23.8元,高1.3%,成交51万股。
药明巨诺是内地临床及临床前阶段细胞治疗公司,由药明康德(02359.HK)及美国医药研发平台Juno共同投资。是次来港上市共发售9,769.2万股,并已引入包括Rock Springs Capital、橡树资本管理、高瓴基金及太平资产管理等10名基石投资者,合共认购4,884.25万股;其中10%公开发售获448.4倍超购,认购一手中签率仅5%;股份以招股范围(20-23.8元)上限定价,料集资净额约21.97亿元,主要用作有关relma-cel及JWCAR129研发活动、建立专门内部销售与营销团队将relmacel推广至中国各地、用作有关其他临床前候选产品、透过行使Acepodia选择权获得Acepodia许可,以及用作新潜在收购和引进授权机会等。上市联席保荐人分别为高盛及瑞银。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.